Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Fact Sheet Nr. 155.

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
156kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 250 Oesophagus WI Digestive system > WI 300-387 Stomach
Language:	English
Series Name:	Fact Sheet Nr. 155
Deposited on:	17 Nov 2023 15:21
Last Modified:	17 Nov 2023 15:21

Repository Staff Only: item control page